News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Barinthus Biotherapeutics (NASDAQ:BRNS) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.

Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-CMA, HFWA, BRNS, and FITB

Barinthus Biotherapeutics (NASDAQ:BRNS) had its price target raised by analysts at HC Wainwright from $3.00 to $4.00. They now have a "buy" rating on the stock.

Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments

5/7/2025

08:00 am

brns

10.4%

MISS

Form 8-K Barinthus Biotherapeutic For: Dec 10

Form 10-Q Barinthus Biotherapeutic For: Sep 30

Form 8-K Barinthus Biotherapeutic For: Nov 07

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}